HomeCompareAVEFF vs PFE

AVEFF vs PFE: Dividend Comparison 2026

AVEFF yields 44444.44% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVEFF wins by $1.4802188700273396e+23M in total portfolio value
10 years
AVEFF
AVEFF
● Live price
44444.44%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.4802188700273396e+23M
Annual income
$147,369,615,738,581,320,000,000,000,000.00
Full AVEFF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — AVEFF vs PFE

📍 AVEFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVEFFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVEFF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVEFF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVEFF
Annual income on $10K today (after 15% tax)
$3,777,777.78/yr
After 10yr DRIP, annual income (after tax)
$125,264,173,377,794,110,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, AVEFF beats the other by $125,264,173,377,794,110,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVEFF + PFE for your $10,000?

AVEFF: 50%PFE: 50%
100% PFE50/50100% AVEFF
Portfolio after 10yr
$7.401094350136698e+22M
Annual income
$73,684,807,869,290,660,000,000,000,000.00/yr
Blended yield
99.56%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

AVEFF
No analyst data
Altman Z
-49.2
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVEFF buys
0
PFE buys
0
No recent congressional trades found for AVEFF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVEFFPFE
Forward yield44444.44%6.20%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1.4802188700273396e+23M$51.1K
Annual income after 10y$147,369,615,738,581,320,000,000,000,000.00$27,210.54
Total dividends collected$1.4797905017086652e+23M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AVEFF vs PFE ($10,000, DRIP)

YearAVEFF PortfolioAVEFF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$4,455,144$4,444,444.44$9,161$701.38+$4.45MAVEFF
2$1,855,294,292$1,850,527,287.41$8,610$859.79+$1855.29MAVEFF
3$722,201,114,647$720,215,949,754.98$8,366$1,081.25+$722201.11MAVEFF
4$262,786,638,114,837$262,013,882,922,164.10$8,483$1,405.66+$262786638.11MAVEFF
5$89,382,811,928,504,960$89,101,630,225,722,080.00$9,084$1,907.24+$89382811928.50MAVEFF
6$28,419,510,536,946,614,000$28,323,870,928,183,110,000.00$10,418$2,732.78+$28419510536946.60MAVEFF
7$8,446,906,587,814,894,000,000$8,416,497,711,540,360,000,000.00$13,007$4,193.56+$8446906587814894.00MAVEFF
8$2,346,953,255,508,951,600,000,000$2,337,915,065,459,989,300,000,000.00$18,010$7,005.87+$2346953255508951552.00MAVEFF
9$609,599,312,292,179,560,000,000,000$607,088,072,308,785,000,000,000,000.00$28,216$12,979.89+$609599312292179607552.00MAVEFF
10$148,021,887,002,733,950,000,000,000,000$147,369,615,738,581,320,000,000,000,000.00$51,081$27,210.54+$1.4802188700273396e+23MAVEFF

AVEFF vs PFE: Complete Analysis 2026

AVEFFStock

Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.

Full AVEFF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this AVEFF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVEFF vs SCHDAVEFF vs JEPIAVEFF vs OAVEFF vs KOAVEFF vs MAINAVEFF vs JNJAVEFF vs MRKAVEFF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.